… -line treatment in RCC, and discuss the difficulties in their interpretation in the context of
treatment sequence. We … to anti-angiogenic therapy and their implications for treatment selection. …

… therapeutic options available for the treatment of advanced renal cell carcinoma (RCC).
Most … ) review to determine sequence and combinations for the systemic treatment of mRCC. …

… are determined in these trials, treatment sequencing after documented progression remains
the standard of care. Selection of treatments for a sequencing regimen is often driven by …

… Dose intensity, patient selection and time on treatment may be key factors … the treatment
landscape for refractory renal cell carcinoma. Nonetheless, the optimal treatment sequencing is …

… drugs for the treatment of renal cell carcinoma (including … OS of patients with renal cell
carcinoma. It has been recently … Thus, deciding which is the best sequence to use in patients …

… the 2 sequences. Nevertheless, in patients who will receive SO and SU after first line treatment,
… Future studies of treatment sequencing could include the collection of biomarker data on …

… Until recently, cytokine therapy provided the mainstay of treatment for metastatic renal cell
carcinoma (mRCC), with interferon (IFN) and interleukin-2 (IL-2) providing clinical benefit …

… The aim of this study was to compare the two most common treatment sequences, VEGFi-rTKI-mTORi
versus VEGFi-mTORi-rTKI, with regard to treatment efficacy and toxicity. …

… Another retrospective study of the International Metastatic Renal Cell Carcinoma database
examined patients treated with first-line anti-VEGF therapy that had primary resistance (ie, PD …

… these 2 sequences in our study raises important questions related to the optimal treatment
schema for patients with renal cell carcinoma and the maximization of treatment benefit when …